Thursday, October 27, 2016
Minerva neurosciences announces positive data from six-month extension of phase iib trial of min-101 monotherapy in schizophrenia.
Minerva neurosciences -min-101 was reported to be well tolerated at both doses over entire 36-week duration of study by schizophrenic patients.
Minerva neurosciences -positive symptoms were observed to remain stable through extension period as measured by panss positive symptom subscale score.
Says extension data also confirm that min-101 at doses tested did not have an effect on extra-pyramidal symptoms.
Source : reuters.com
